[
    [
        {
            "time": "",
            "original_text": "【天风医药】健帆生物：业绩预告回归高增长态势，激励考核提升业绩信心",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩预告",
                    "高增长",
                    "激励考核",
                    "业绩信心"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】健帆生物：业绩预告回归高增长态势，激励考核提升业绩信心",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：预计2019年净利润5.23亿元至6.03亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "净利润",
                    "2019年",
                    "5.23亿元",
                    "6.03亿元"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：预计2019年净利润5.23亿元至6.03亿元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "健帆生物（300529）：业绩符合预期，Q4恢复快速增长！【动态点评|西南证券医药朱国广团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "300529",
                    "业绩",
                    "符合预期",
                    "Q4",
                    "快速增长",
                    "西南证券",
                    "医药",
                    "朱国广团队"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物（300529）：业绩符合预期，Q4恢复快速增长！【动态点评|西南证券医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]